Windtree Therapeutics, Inc. EV/Sales

EV/Sales of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Sales growth rates and interactive chart. Compares the total enterprise value of a company to its sales. It is a more accurate measure of business value, as it takes into account cash and debt on the balance sheet. A company with large cash holdings and no debt will show a significantly lower EV/S than P/S ratio.

Highlights and Quick Summary

Current EV/Sales of Windtree Therapeutics, Inc. is 271.93 (as of December 30, 2019)
  • EV/Sales for the quarter ending December 30, 2019 was 271.93 (a 22.36% increase compared to previous quarter)
  • Year-over-year quarterly EV/Sales increased by 2296.24%
  • Annual EV/Sales for 2019 was 271.93 (a 2296.24% increase from previous year)
  • Annual EV/Sales for 2018 was 11.35 (a -49.72% decrease from previous year)
  • Annual EV/Sales for 2017 was 22.57 (a 53.62% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Sales of Windtree Therapeutics, Inc.

Most recent EV/Salesof WINT including historical data for past 10 years.

Interactive Chart of EV/Sales of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. EV/Sales for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 271.93 222.24 89.55 271.93
2018 11.35 19.49 23.19 17.45 11.35
2017 22.57 12.6 8.0 12.46 22.57
2016 14.69 18.93 22.83 10.68 14.69
2015 6.87 6.87 27.16 29.11 6.87
2014 26.23 70.53 83.56 360.28 26.23
2013 145.81 179.91 66.06 0.0 145.81
2012 0.0
2011 0.0 0.0 0.0

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.